FindTrial
Sign In

Delirium treatment at the geriatric ward (DELTa G) Treatment of delirium: rivastigmine or haloperidol as primary treatment for delirium in delirious patients on a geriatric ward. A randomized placebo-controlled study.

Delirium treatment at the geriatric ward (DELTa G) Treatment of delirium: rivastigmine or haloperidol as primary treatment for delirium in delirious patients on a geriatric ward. A randomized placebo-controlled study.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON29295
Enrollment
100
Registered
2005-11-23
Start date
2006-01-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

radndomized placebo-controlled study on a geriatric ward.

Interventions

1. Haloperidol
2. Rivastigmine.

Sponsors

trial medication is sponsored by Novartis
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients on a geriatric ward and delirium.

Exclusion criteria

Exclusion criteria: 1. Already use of rivastigmine/donepezil or galantamine; 2. Parkinson(ism).

Design outcomes

Primary

MeasureTime frame
Length of delirium.—

Secondary

MeasureTime frame
1. Length of stay in hospital; 2. Severity of delirium; 3. Need of escape medication; 4. Functional status, 3, 6 and 13 weeks after delirium; 5. Cognition.—

Contacts

Public ContactP.L.J. Dautzenberg

Jeroen Bosch Hospital, Department Geriatrics, P.O. Box 90153

p.dautzenberg@jbz.nl+31 (0)73 6998629

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)